Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections

다국어 초록 (Multilingual Abstract)

Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomialpathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limitsthe available therapeutic agents, makes the infection difficult to treat, and is associatedwith a greater risk of death. In this review, we provide an update on the epidemiology,resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.

참고문헌 (Reference)

1 Lee K, "Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea" 33 : 520-524, 2009

2 Fishbain J, "Treatment of Acinetobacter infections" 51 : 79-84, 2010

3 Cookson B, "The working party guidance on the control of multi-resistant AcinetobacterOutbreaks"

4 Fournier PE, "The epidemiology and control of Acinetobacter baumannii in health care facilities" 42 : 692-699, 2006

5 Park KH, "The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies" 8 : e65026-, 2013

6 Apisarnthanarak A, "Thammasat University Pandrug-Resistant Acinetobacter baumannii Control Group. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study" 47 : 760-767, 2008

7 Jankowski S, "Susceptibility of isolates of Acinetobacter anitratus and Acinetobacter lwoffii to the bactericidal activity of normal human serum" 4 : 255-260, 1992

8 Haseley SR, "Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter junii strain 65" 245 : 477-481, 1997

9 Kim DH, "Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands" 57 : 5239-5246, 2013

10 Denton M, "Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit" 56 : 106-110, 2004

11 Husni RN, "Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients" 115 : 1378-1382, 1999

12 Yang SC, "Prevalence of antibiotics resistance and OXA carbapenemases genes in multidrug-resistant Acinetobacter baumannii isolates in central Taiwan" 29 : 601-604, 2010

13 Tunkel AR, "Practice guidelines for the management of bacterial meningitis" 39 : 1267-1284, 2004

14 Choi CH, "Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells" 7 : 1127-1138, 2005

15 Wybo I, "Outbreak of multidrug-resistant Acinetobacter baumannii in a Belgian university hospital after transfer of patients from Greece" 67 : 374-380, 2007

16 Idzenga D, "Outbreak of Acinetobacter genomic species 3 in a Dutch intensive care unit" 63 : 485-487, 2006

17 Smolyakov R, "Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment" 54 : 32-38, 2003

18 Wisplinghoff H, "Nosocomial bloodstream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study" 39 : 309-317, 2004

19 Wisplinghoff H, "Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States" 64 : 282-290, 2012

20 Wisplinghoff H, "Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility" 31 : 690-697, 2000

21 Smith MG, "New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis" 21 : 601-614, 2007

22 Gaynes R, "National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli" 41 : 848-854, 2005

23 Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance" 18 : 268-281, 2012

24 Gordon NC, "Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance" 35 : 219-226, 2010

25 Lopez-Cortes LE, "Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii : analysis of a multicentre prospective cohort" 2014

26 Gayoso CM, "Molecular mechanisms involved in the response to desiccation stress and persistence in Acinetobacter baumannii" 13 : 460-476, 2014

27 Kraniotaki E, "Molecular investigation of an outbreak of multidrug-resistant Acinetobacter baumannii, with characterisation of class 1 integrons" 28 : 193-199, 2006

28 Schleicher X, "Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009)" 19 : 737-742, 2013

29 Costerton JW, "Microbial biofilms" 49 : 711-745, 1995

30 Kim BN, "Management of meningitis due to antibiotic-resistant Acinetobacter species" 9 : 245-255, 2009

31 Euzéby JP, "List of bacterial names with standing in nomenclature:a folder available on the internet" 47 : 590-592, 1997

32 Raetz CR, "Lipopolysaccharide endotoxins" 71 : 635-700, 2002

33 Carbonne A, "Investigation of a nosocomial outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting" 60 : 14-18, 2005

34 Lee SY, "Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital" 52 : 931-939, 2014

35 Dalfino L, "High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study" 54 : 1720-1726, 2012

36 Zarrilli R, "Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages" 41 : 11-19, 2013

37 Morgan DJ, "Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers" 31 : 716-721, 2010

38 Valencia R, "Fernández-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital" 30 : 257-263, 2009

39 Prasad P, "Excess deaths associated with tigecycline after approval based on noninferiority trials" 54 : 1699-1709, 2012

40 Podnos YD, "Eradication of multi-drug resistant Acinetobacter from an intensive care unit" 2 : 297-301, 2001

41 Chuang YY, "Epidemiological investigation after hospitalising a case with pandrug-resistant Acinetobacter baumannii infection" 72 : 30-35, 2009

42 Montravers P, "Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies" 68 (68): ii15-ii24, 2013

43 Eckmann C, "Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies" 68 (68): ii25-ii35, 2013

44 Betrosian AP, "Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia" 56 : 432-436, 2008

45 Dorsey CW, "Detection and analysis of iron uptake components expressed by Acinetobacter baumannii clinical isolates" 41 : 4188-4193, 2003

46 Park YK, "Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii" 37 : 525-530, 2011

47 Wilks M, "Control of an outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation" 27 : 654-658, 2006

48 Pimentel JD, "Control of an outbreak of multi-drug-resistant Acinetobacter baumannii in an intensive care unit and a surgical ward" 59 : 249-253, 2005

49 Urban C, "Considerations in control and treatment of nosocomial infections due to multidrug- resistant Acinetobacter baumannii" 36 : 1268-1274, 2003

50 Lee SY, "Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of Acinetobacter species from a Korean university hospital" 51 : 1924-1926, 2013

51 최준용, "Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia" 연세대학교의과대학 47 (47): 63-69, 2006

52 Paul M, "Combination therapy for carbapenem-resistant Gram-negative bacteria" 2014

53 Sirijatuphat R, "Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem - Resistant Acinetobacter baumannii Infections: A Preliminary Study" AAC 2014

54 Cai Y, "Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies" 67 : 1607-1615, 2012

55 Moffatt JH, "Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production" 54 : 4971-4977, 2010

56 Nation RL, "Colistin in the 21st century" 22 : 535-543, 2009

57 Durante-Mangoni E, "Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial" 57 : 349-358, 2013

58 Chusri S, "Clinical outcomes of hospitalacquired infection with Acinetobacter nosocomialis and Acinetobacter pittii" 58 : 4172-4179, 2014

59 Farrell DJ, "Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)" 43 : 533-539, 2014

60 Queenan AM, "Carbapenemases: the versatile betalactamases" 20 : 440-458, 2007

61 Poirel L, "Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology" 12 : 826-836, 2006

62 Martí S, "Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species" 4 : 5-, 2011

63 De Jong G, "Back to basics--optimizing the use of available resources during an outbreak of multi-drug resistant Acinetobacter spp" 57 : 186-187, 2004

64 Tomaras AP, "Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii:involvement of a novel chaperone-usher pili assembly system" 149 : 3473-3484, 2003

65 King AM, "Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance" 510 : 503-506, 2014

66 Hilf M, "Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients" 87 : 540-546, 1989

67 Longo B, "An outbreak of Acinetobacter baumannii in an intensive care unit: epidemiological and molecular findings" 64 : 303-305, 2006

68 Oliveira MS, "Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp" 61 : 1369-1375, 2008

69 Villegas MV, "Acinetobacter outbreaks, 1977-2000" 24 : 284-295, 2003

70 Falagas ME, "Acinetobacter infections: a growing threat for critically ill patients" 136 : 1009-1019, 2008

71 Lee YC, "Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes." 66 : 1839-1846, 2011